ACD-101

ACD-101 is systemically administered via intravenous injection and reaches tumour cells over the intact blood-brain-barrier due to the pharmacological properties of the molecule. Glioma cells actively take up and retain ACD-101, allowing for diagnosis (124I-ACD-101) and therapy (131I-ACD-101). The treatment of inaccessibly localized tumours (e.g basal parts of the brain), or unrecognized micrometastases which cannot be sufficiently treated by surgery or radiation therapy becomes possible.

The anti-tumour effect induced by 131I-ACD-101 endo-radiotherapy is different in extent and nature compared to external field radiation. While endo-radiotherapy is cytocidal for glioma cells, conventional radiation therapy is only cytostatic (i.e. inhibiting growth).

Efficacy

Actively transported over intact blood brain barrier
Preferentially taken up and retained by tumor cells
Cytotoxic for glioma cells, inducing necrosis and apoptosis
Multimodal mode of action, reducing risk of resistance development Synergistic with XRT & other therapies

Safety

Systemic instead of local approach, avoiding intracerebral procedures (as in brachytherapy, chemo-wafers)
Toxicity profile well characterised (thyroid 131I therapy well established)

In the following sub-sections we present selected results of our development:

in vitro results (test tube experiments) and
in vivo results (living organism experiments)

First human results can be found in the chapters diagnosis and therapy.

Contact Therapeia

Therapeia GmbH & Co. KG
Veilchenweg 38
01326 Dresden
Germany

Tel: +49 (0)351 4188 00000
Fax: +49 (0)351 4188 00009

E-Mail: info@therapeia.info

or just use our contact form

ACD-101

Efficacy

Safety

Contact Therapeia

Login